Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in adults with inadequately controlled eosinophilic COPD
CTR20254266Phase 3Active
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lunsekimig in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Dec 2025; status: active.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20254266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254266.